What is the half-life of PTD-DBM?

PTD-DBM has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute PTD-DBM?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

What is the half-life of PTD-DBM?

PTD-DBM has a half-life of Unknown, which is why it's typically administered As needed for optimal therapeutic effect.

How do I reconstitute PTD-DBM?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Preclinical

PTD-DBM

Also known as: PTD-DBM Peptide, Wnt Activator Peptide

Overview

Key Facts

Primary Goal: Research and therapeutic applications of PTD-DBM

Disrupts CXXC5-Dishevelled protein-protein interaction. Releases suppression of Wnt/beta-catenin signaling in hair follicle stem cells.

Dosing Information

Half-Life

~2-4 hours (estimated from preclinical data)

Typical Dose

0.5–2 mg

Frequency

Once daily (topical application to scalp)

Cycle Length

12-24 weeks for initial hair growth assessment

Administration Routes:

subcutaneoustopical

Benefits

Stimulates new hair follicle neogenesis (not just preservation)
Activates hair follicle stem cells via Wnt pathway
Accelerates wound healing with hair follicle regeneration
Potential to restore follicles in areas of complete hair loss
Promotes both hair growth and skin regeneration simultaneously

Side Effects

Scalp irritation or redness (preclinical data)uncommonmild

Theoretical risk of excessive Wnt activation (monitored in studies)uncommonmild

Limited human safety data availableuncommonmild

Mechanism of Action

Disrupts CXXC5-Dishevelled protein-protein interaction

Releases suppression of Wnt/beta-catenin signaling in hair follicle stem cells

Promotes conversion of resting telogen follicles to active anagen phase

Stimulates de novo hair follicle formation from dermal stem cells

PTD domain enables cell membrane penetration without additional carriers

Contraindications

Do not use this peptide if any of the following apply:

Active skin cancer or precancerous lesions (Wnt pathway involvement in tumorigenesis)
Pregnancy or breastfeeding
Inflammatory scalp conditions (untreated psoriasis, severe dermatitis)

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

Published in 2017 by researchers at Yonsei University (South Korea) in the Journal of Investigative Dermatology, PTD-DBM demonstrated new hair follicle formation in mice — a result not achieved by any currently approved hair loss treatment. The study showed that topical application to wound sites produced fully functional hair follicles from stem cells. The mechanism targets CXXC5, a negative regulator of Wnt signaling that is overexpressed in balding scalp. While extremely promising, the peptide remains in preclinical development with human trials pending.

Frequently Asked Questions

Common questions about PTD-DBM

UK-Specific Information

Exclusive data points and guidance for UK residents using PTD-DBM

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Generate a trackable link to share this peptide information on TikTok